BioNxt Solutions Inc. specializes in the research, development, and manufacturing of advanced drug formulations and delivery systems in Austria, Germany, and Switzerland. A significant concern is its negative return on assets (ROA) of -211.9%, indicating inefficiencies in generating profit from assets. Additionally, the current ratio of 0.06 raises liquidity concerns, suggesting potential difficulties in meeting short-term obligations. The stock's recent decline of 11.67% may reflect these financial challenges, warranting caution for potential investors.
Loading financial metrics...
Company has $4K in cash but burned $847K last quarter. At this burn rate, only 0.0 quarters of runway remain without additional financing.
Revenue fell 29.3% year-over-year from $31K to $22K. The decline has persisted for multiple quarters.
Company posted a loss of $-6.0M over the last year, representing 27871.5% of revenue.
Debt of $7.1M is 1667.1x the company's cash position of $4K.
Operating cash flow has been negative for 3 consecutive quarters, burning $3.4M over the last year.
Gross margin expanded by 237.2 percentage points, indicating improved pricing power or cost efficiency.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2025-Q2 (June 30, 2025)